Demonstration Case · Created From Public-Record Data · Real Forensic Patterns · Read OnlyConstructed from real court documents, public filings, and forensic accounting archetypes.

Prepared by Quarare LLC · Forensic Analysis Platform

Theranos — Revenue and Capability Misrepresentation: A Quarare Forensic Analysis

Illustrative case study based on publicly-documented matters.

Methodology: v1.0.0
Status: Finalized
Provenance: Public-record sources

Drop your documents here, or click to browse

PDF · DOCX · XLSX · CSV · JPG · PNG — up to 50 documents, 100MB each

Demo mode — uploads are not processed in this preview. See the sample engagement workflow below.

Total

Scored

Mean Composite

Overridden

SortOCROverridesReliability

15 of 15

File	Type	Size	OCR	Reliability	Uploaded
Theranos-USPTO-miniLab-Patent-Filings-and-Office-Actions-2010-2015.pdf	PDF	1.4 MB	ready	91	Sep 8, 2017, 11:42 UTC	▶
Theranos-Board-of-Directors-Minutes-2013-2015.pdf	PDF	2.1 MB	ready	78	Sep 8, 2017, 11:14 UTC	▶
Theranos-Voided-Patient-Test-Results-Notification-Bundle-2016-04.pdf	PDF	8.8 MB	ready	87	Jul 19, 2017, 10:14 UTC	▶
Theranos-Holmes-Balwani-Schultz-Email-Correspondence-2014-2015.pdf	PDF	2.4 MB	failed	79	May 16, 2017, 11:00 UTC	▶
Extraction error: OCR engine produced low-confidence output across the document (mean character confidence 0.38) due to dense email-header text, layered forwarding indents, handwritten counsel-margin annotations on the printed exhibits, and SEC-applied redactions of non-public counsel-product material. Manual transcription queued — see analyst note in engagement log.
Erika-Cheung-CMS-Complaint-and-Supporting-Documentation-2015-09.pdf	PDF	1.4 MB	ready	87	Apr 4, 2017, 09:42 UTC	▶
Tyler-Shultz-Whistleblower-Memorandum-and-NYSDOH-Submission-2014-2015.pdf	PDF	1.7 MB	ready	87	Apr 4, 2017, 09:14 UTC	▶
Department-of-Defense-Theranos-Contract-and-Correspondence-Records-2012-2015.pdf	PDF	964.9 KB	ready	94	Feb 8, 2017, 11:14 UTC	▶
Safeway-Theranos-Wellness-Pilot-Contract-and-Status-Reports-2010-2015.pdf	PDF	3.1 MB	ready	89	Nov 22, 2016, 10:18 UTC	▶
Walgreens-Theranos-Master-Services-Agreement-and-Amendments-2010-2015.pdf	PDF	4.3 MB	ready	90	Oct 18, 2016, 11:14 UTC	▶
CMS-Sanction-Letter-and-CLIA-Revocation-Theranos-2016-07-08.pdf	PDF	476.6 KB	ready	97	Jul 15, 2016, 10:42 UTC	▶
Theranos-miniLab-Proficiency-Testing-Raw-Data-2014-2015.pdf	PDF	21.4 MB	pending	60	May 3, 2016, 11:42 UTC	▶
Theranos-Edison-TSPU-Validation-Report-Compilation-2013-2015.pdf	PDF	12.2 MB	ready	34	Apr 12, 2016, 10:14 UTC	▶
CMS-Form-2567-Theranos-Newark-Lab-Statement-of-Deficiencies-2016-01-25.pdf	PDF	1.2 MB	ready	96	Feb 4, 2016, 09:18 UTC	▶
Theranos-RDV-DeVos-Family-Office-Investor-Pitch-Deck-2014-10.pdf	PDF	7.1 MB	ready	61	Dec 8, 2015, 10:12 UTC	▶
Theranos-PFM-Partner-Fund-Series-C-2-Investor-Pitch-Deck-2014-02.pdf	PDF	8.4 MB	ready	63	Nov 12, 2015, 09:32 UTC	▶

Swipe table to see more columns →

Override actions are disabled in demo mode.

Surfaced

Promoted

Under Review

Dismissed

Insight I-1

InconsistencyHigh confidencePromoted

Edison proficiency-testing instrument record contradicts internal validation summaries

The Newark CLIA-lab LIMS export (D-002) shows systematic Edison-and-TSPU proficiency-testing failures across HbA1c, TSH, PSA, and Vitamin D challenges during 2014-2015, with documented segregation of Edison-generated proficiency challenges from the CAP/CLIA-reportable stream. The internal validation summaries (D-001) record the same period's validations as "passing" under altered acceptance criteria reflected in post-hoc edits to the summary tables. The CMS Form 2567 (D-003) independently establishes "immediate jeopardy" findings across the same operational period.

Supporting Documents

DOC-THERANOS-001, DOC-THERANOS-002, DOC-THERANOS-003

Promoted To

Finding 1: Edison and TSPU Devices Failed Proficiency Testing — Capability Representations Materially Unsupported

Insight I-2

ConcentrationHigh confidencePromoted

Approximately 890,000 patient test results voided — diagnostic of systemic lab-quality failure

In March-May 2016 the Theranos replacement lab director Kingshuk Das, M.D., acting under his independent CLIA fitness obligations, voided or corrected approximately 890,000 patient test results spanning two years of Theranos clinical operations (D-012). The voiding determination is independently produced from inside the organization by a lab-director-of-record acting after the prior management group, and is corroborated by the CMS regulatory record (D-003, D-004). The voided-result count is the operational consequence of the capability gap surfaced in I-1.

Supporting Documents

DOC-THERANOS-003, DOC-THERANOS-004, DOC-THERANOS-012

Promoted To

Finding 2: Voided Patient Test Results Establish Systemic Clinical-Laboratory Quality Failure

Insight I-3

InconsistencyHigh confidencePromoted

Counterparty-side records contradict represented status of Walgreens and Safeway relationships

Walgreens-side production (D-005) records the deteriorating relationship trajectory from Q4 2014 (Amendment Three) forward and includes the Hunsaker capability-verification memorandum that became dispositive on what Walgreens was told once the operational reality was independently established. Safeway-side production (D-006) records the August 2014 internal note "no contact from Theranos in seven months" — directly preceding the October 2014 RDV investor pitch deck (D-008) representing the Safeway relationship as the basis of 2015 expansion plans. The counterparty records and the contemporaneous investor representations are directly inconsistent.

Supporting Documents

DOC-THERANOS-005, DOC-THERANOS-006, DOC-THERANOS-007, DOC-THERANOS-008

Promoted To

Finding 3: Walgreens and Safeway Counterparty Relationships Induced Through Materially False Device-Capability Statements

Insight I-4

OmissionHigh confidencePromoted

DoD procurement record establishes ~$300K cumulative spend; no battlefield or medevac deployment

The DoD response (D-014) and the publicly accessible USASpending.gov procurement registry independently establish that the actual Theranos-DoD commercial relationship consists of three small-business research contracts with cumulative value of approximately $300,000 across 2012-2015. No record of any operational "battlefield" or "medevac helicopter" deployment exists in any DoD record system. The Series C-2 investor pitch decks (D-007, D-008) represent contrary deployment claims as material to the Theranos business case. The verification procedure (USASpending.gov search) requires no privileged access.

Supporting Documents

DOC-THERANOS-007, DOC-THERANOS-008, DOC-THERANOS-014

Promoted To

Finding 4: Department of Defense Deployment Claims Unsupported by Any Procurement Record

Insight I-5

SequenceHigh confidencePromoted

Whistleblower retaliation pattern corroborates concealment intent across two convergent observer sequences

The Tyler Shultz sequence (internal escalation 2014, NYSDOH submission April 2014 under alias "Colin Ramirez", subsequent legal-action threats and NDA enforcement) and the Erika Cheung sequence (internal escalation 2014, CMS complaint September 2015, subsequent private-investigator surveillance and threatened litigation) are independently produced, contemporaneously contemporaneous, and substantively consistent on both the operational failures observed and the management retaliatory response. The convergent two-witness pattern is the canonical documentary signature distinguishing intentional concealment from optimistic projection error.

Supporting Documents

DOC-THERANOS-009, DOC-THERANOS-010, DOC-THERANOS-011

Promoted To

Finding 5: Whistleblower Retaliation Pattern Corroborates Concealment Intent and Operational Awareness of Capability Gap

Insight I-6

InconsistencyHigh confidencePromoted

Board-presentation content substantively mirrors materially false investor-pitch content

Board minutes (D-013) record board-meeting presentations on the company's product, partnership, and financial status that substantively mirror the contemporaneous investor pitch-deck content (D-007, D-008) — including the same capability representations, partnership-status representations, and DoD-deployment representations now established as materially false. The June 2014 minutes record Holmes contemplating "ending the Safeway relationship" without concurrent disclosure that the same relationship was being represented to investors as the basis of 2015 expansion plans. The board's information set during the relevant period did not include the independent technical, counterparty, or regulatory records that would have surfaced the discrepancies.

Supporting Documents

DOC-THERANOS-007, DOC-THERANOS-008, DOC-THERANOS-013

Promoted To

Finding 6: Board of Directors Misled — Financial Projections Premised on Capabilities That Did Not Exist

Total Findings

Finalized

Mean Composite

Flagged

Statement of Opinion

Theranos's proprietary Edison and TSPU ("Theranos Sample Processing Unit") analyzers, represented to investors as capable of performing comprehensive laboratory testing from a finger-stick blood sample, failed CAP/CLIA proficiency-testing requirements across multiple analytes during the relevant 2013-2015 period. The capability representations made in the Series C-2 investor pitch materials (D-007, D-008) — including the recurring claim of "over 1,000 CPT codes" capability — are not supported by the underlying proficiency-testing record or by the patent-claim scope.

The finding rests on three independent evidentiary streams:

(1) **Direct proficiency-testing record (D-002).** The Newark CLIA-lab LIMS export reflects systematic failures across HbA1c, TSH, prostate-specific antigen (PSA), and Vitamin D challenges, with documented operational pattern of segregating the Edison-generated proficiency challenges from the CAP/CLIA-reportable proficiency-challenge stream — a workaround that produced apparently-acceptable CAP results while internal Edison results showed continued failure.

(2) **Federal regulatory determination (D-003, D-004).** The CMS Form 2567 Statement of Deficiencies (D-003), issued following the November 20, 2015 on-site survey of the Newark lab, made the landmark finding of "immediate jeopardy to patient health and safety" under 42 CFR § 493.1100 — a determination that requires, under CMS surveyor protocol, contemporaneous evidence of systemic method-validation and quality-control failure. The CMS Sanction Letter (D-004) revoked the CLIA certificate effective approximately one year following the survey and prohibited Elizabeth Holmes from operating a clinical laboratory for two years. Both documents are independently produced federal regulatory determinations made on the basis of contemporaneous on-site observation.

(3) **Patent-claim-scope cross-reference (D-015).** The USPTO patent record for the Theranos miniLab and TSPU patent family describes specific technical mechanisms with narrow analyte ranges. The disjunction between the patent-claim scope and the "over 1,000 CPT codes" investor representation is directly observable on cross-reference and is independent of any CLIA-lab operational record.

The internal validation reports (D-001) produced by Theranos R&D are themselves the subject of examination rather than corroborative evidence: the bundle includes 14 revision-set artifacts for the Edison HbA1c validation alone, with substantive parameter changes between revisions and post-hoc edits to summary tables re-categorizing borderline results as "passing" under altered acceptance criteria. This pattern is the documentary signature of an internal-validation process that does not meet the AICPA Statement on Standards for Forensic Services / ACFE Fraud Examiners Manual benchmarks for independent technical validation.

The forensic significance of this finding for engagement methodology is that **capability verification of a development-stage diagnostic-device claim cannot be performed on the basis of the developer's own validation reports**; it requires independent technical testing, third-party proficiency comparison, and validation-study review by an independent CLIA-credentialed reviewer. The procedures that would have established the capability gap were available to Theranos's investor base during the 2013-2015 fundraising period and were not performed.

Supporting Evidence

Doc ID	Filename	Reliability
DOC-THERANOS-001	Theranos-Edison-TSPU-Validation-Report-Compilation-2013-2015.pdf	34
DOC-THERANOS-002	Theranos-miniLab-Proficiency-Testing-Raw-Data-2014-2015.pdf	60
DOC-THERANOS-003	CMS-Form-2567-Theranos-Newark-Lab-Statement-of-Deficiencies-2016-01-25.pdf	96
DOC-THERANOS-004	CMS-Sanction-Letter-and-CLIA-Revocation-Theranos-2016-07-08.pdf	97
DOC-THERANOS-007	Theranos-PFM-Partner-Fund-Series-C-2-Investor-Pitch-Deck-2014-02.pdf	63
DOC-THERANOS-008	Theranos-RDV-DeVos-Family-Office-Investor-Pitch-Deck-2014-10.pdf	61
DOC-THERANOS-015	Theranos-USPTO-miniLab-Patent-Filings-and-Office-Actions-2010-2015.pdf	91

Daubert Four-Factor Analysis

Testability92

The capability hypothesis is directly testable against CAP/CLIA proficiency-testing standards (a well-defined external benchmark), against the patent-claim scope (a public-record technical specification), and against any independent technical-validation procedure performed on the analyzers themselves. The hypothesis is falsified by the production of independent validation evidence demonstrating capability; no such evidence exists in the engagement record.

Peer Review88

Capability-verification methodology is documented in CLIA regulations (42 CFR Part 493), in the FDA 21 CFR Part 809 framework for in vitro diagnostic devices, in the AICPA Statement on Standards for Forensic Services, and in standard practitioner texts on life-sciences forensic investigation. The methodology applied here is consistent with the procedures adopted by CMS surveyors in the November 2015 inspection.

Error Rate90

Proficiency-testing failure determinations are deterministic against CAP/CLIA acceptance criteria; the patent-claim-versus-representation disjunction is binary and observable on direct comparison. The error rate on the CMS regulatory finding is bounded by CMS surveyor protocol and is not subject to reasonable challenge given the convergent operational evidence.

General Acceptance90

Capability verification through proficiency-testing review, patent-claim cross-reference, and regulatory-record analysis is generally accepted across life-sciences forensic practice, FDA enforcement, and securities-litigation expert work involving development-stage diagnostic companies. The methodology is applied routinely by Big-4 forensic firms and by specialized life-sciences-diligence boutiques.

Composite90

Limitations

The finding addresses capability of the Edison and TSPU analyzers against the represented "over 1,000 CPT codes" scope; the actual operational capability for the limited set of analytes for which Theranos performed any internal validation (approximately 12 analytes on the TSPU) is not within the present scope and is the subject of a separate technical workpaper. The finding does not opine on the technical feasibility of the broader Theranos research roadmap; it opines only on the gap between represented capability and demonstrated capability during the relevant period.

Subject S-001

Elizabeth A. Holmes

Principal; Founder, Chief Executive Officer, and Chairman, Theranos, Inc. (2003 – June 2018); Class B supermajority-voting shareholder following the early-2014 capital-structure change

Key Documents

DOC-THERANOS-007Theranos-PFM-Partner-Fund-Series-C-2-Investor-Pitch-Deck-2014-02.pdf
DOC-THERANOS-008Theranos-RDV-DeVos-Family-Office-Investor-Pitch-Deck-2014-10.pdf
DOC-THERANOS-009Theranos-Holmes-Balwani-Schultz-Email-Correspondence-2014-2015.pdf
DOC-THERANOS-013Theranos-Board-of-Directors-Minutes-2013-2015.pdf
DOC-THERANOS-014Department-of-Defense-Theranos-Contract-and-Correspondence-Records-2012-2015.pdf
DOC-THERANOS-015Theranos-USPTO-miniLab-Patent-Filings-and-Office-Actions-2010-2015.pdf

Notable Patterns

Cover-letter signatory on the Series C-2 investor pitch decks (D-007 Partner Fund Management; D-008 RDV Corp) on Theranos letterhead, containing the materially false representations regarding capability ("over 1,000 CPT codes"), Walgreens/Safeway partnership status, DoD deployment claims, and 2014/2015 financial projections (~$100M / ~$1B versus actual ~$100K 2014 revenue). Chairman of the board presentations recorded in D-013 substantively mirror the investor-deck content. CMS Sanction Letter (D-004) prohibits Holmes from operating a clinical laboratory for two years — an independent regulatory determination of unfitness. Named inventor on the principal miniLab and TSPU patent filings (D-015) with patent-claim scope materially narrower than the corresponding investor-representation scope. Holmes's communications with Tyler Shultz and the related Schultz-family correspondence reflected in D-009 are central to the retaliation-pattern record supporting F-5.

Subject S-002

Ramesh "Sunny" Balwani

Principal lieutenant; President and Chief Operating Officer, Theranos, Inc. (September 2009 – May 2016); personal guarantor of 2009 line of credit; principal of the Theranos clinical-laboratory operations

Key Documents

DOC-THERANOS-001Theranos-Edison-TSPU-Validation-Report-Compilation-2013-2015.pdf
DOC-THERANOS-002Theranos-miniLab-Proficiency-Testing-Raw-Data-2014-2015.pdf
DOC-THERANOS-007Theranos-PFM-Partner-Fund-Series-C-2-Investor-Pitch-Deck-2014-02.pdf
DOC-THERANOS-008Theranos-RDV-DeVos-Family-Office-Investor-Pitch-Deck-2014-10.pdf
DOC-THERANOS-009Theranos-Holmes-Balwani-Schultz-Email-Correspondence-2014-2015.pdf
DOC-THERANOS-012Theranos-Voided-Patient-Test-Results-Notification-Bundle-2016-04.pdf

Notable Patterns

Principal operational supervisor of the Newark, CA clinical-laboratory function during the relevant 2013-2015 commercial period; signatory on internal validation reports in D-001 and signatory or counter-signatory on the LIMS-extraction approvals reflected in D-002. Co-author with Holmes of the Series C-2 investor materials (D-007, D-008) and the contemporaneous financial-projection content. Direct correspondence reflected in D-009 records Balwani communicating retaliatory direction toward Tyler Shultz following Shultz's internal escalation in March-April 2014 and following the NYSDOH submission in April 2014. The voided patient-result bundle (D-012), issued in March-May 2016 by Balwani's successor (Kingshuk Das, M.D.) acting under independent CLIA fitness obligations, voided approximately 890,000 patient test results spanning the period of Balwani's direct operational responsibility.

Subject S-003

Theranos Board of Directors (2013-2015 composition)

Subject entity (collective); Theranos, Inc. Board of Directors and board committees during the substantive-conduct window; included George Shultz, Henry Kissinger, William Perry, Sam Nunn, James Mattis, Riley Bechtel, and David Boies (outside counsel) — together with Elizabeth Holmes (Chairman) and participation by Ramesh Balwani

Key Documents

DOC-THERANOS-005Walgreens-Theranos-Master-Services-Agreement-and-Amendments-2010-2015.pdf
DOC-THERANOS-006Safeway-Theranos-Wellness-Pilot-Contract-and-Status-Reports-2010-2015.pdf
DOC-THERANOS-007Theranos-PFM-Partner-Fund-Series-C-2-Investor-Pitch-Deck-2014-02.pdf
DOC-THERANOS-008Theranos-RDV-DeVos-Family-Office-Investor-Pitch-Deck-2014-10.pdf
DOC-THERANOS-013Theranos-Board-of-Directors-Minutes-2013-2015.pdf
DOC-THERANOS-014Department-of-Defense-Theranos-Contract-and-Correspondence-Records-2012-2015.pdf

Notable Patterns

Documented governance anomaly: no board member during the relevant 2013-2015 period possessed clinical-laboratory, diagnostic-medicine, or medical-device engineering background. Board-meeting presentations recorded in D-013 substantively mirror the contemporaneous investor pitch-deck content (D-007, D-008) including the same capability, partnership, and DoD-deployment representations now established as materially false. The June 2014 board minutes record Holmes contemplating "ending the Safeway relationship" without concurrent disclosure of the contradictory investor representations being made at the same time. The collective subject is treated here as a single entity for purposes of the information-asymmetry analysis in F-6; individual board-member-by-board-member conduct review is reserved for separate civil-litigation expert work. The presence on the board of former Defense Secretary William Perry and General James Mattis is the documentary frame against which the F-4 DoD-deployment-representation finding is to be evaluated: investors and the board itself appear to have treated those affiliations as substitutes for direct verification of the DoD-deployment claim — a substitution that is methodologically unsupportable.

Subject S-004

Theranos, Inc.

Subject entity; Delaware corporation; private development-stage medical-diagnostics company; principal places of business Palo Alto and Newark, California; defendant in SEC v. Theranos, Inc. and Elizabeth Holmes, No. 5:18-cv-01602 (N.D. Cal., filed March 14, 2018)

Key Documents

DOC-THERANOS-001Theranos-Edison-TSPU-Validation-Report-Compilation-2013-2015.pdf
DOC-THERANOS-002Theranos-miniLab-Proficiency-Testing-Raw-Data-2014-2015.pdf
DOC-THERANOS-003CMS-Form-2567-Theranos-Newark-Lab-Statement-of-Deficiencies-2016-01-25.pdf
DOC-THERANOS-004CMS-Sanction-Letter-and-CLIA-Revocation-Theranos-2016-07-08.pdf
DOC-THERANOS-005Walgreens-Theranos-Master-Services-Agreement-and-Amendments-2010-2015.pdf
DOC-THERANOS-012Theranos-Voided-Patient-Test-Results-Notification-Bundle-2016-04.pdf
DOC-THERANOS-013Theranos-Board-of-Directors-Minutes-2013-2015.pdf
DOC-THERANOS-015Theranos-USPTO-miniLab-Patent-Filings-and-Office-Actions-2010-2015.pdf

Notable Patterns

Founded 2003 by Elizabeth Holmes following her withdrawal from Stanford during her sophomore year; aspirational technology platform was a portable blood-testing analyzer capable of performing comprehensive laboratory testing from a finger-stick sample. Operating clinical-laboratory function (Newark, CA; CCN 05D2025714) failed the November 2015 CMS on-site survey (D-003) and lost CLIA certification under the July 2016 sanction letter (D-004). The substantive fraud-conduct window covers the late-2013 through 2015 fundraising rounds during which approximately $700M was raised from investors on the basis of the misrepresentations addressed in the findings. The internal R&D validation reports (D-001) are the subject of examination rather than corroborative evidence on capability. The principal commercial partnerships (Walgreens, D-005; Safeway, D-006) and the principal claimed government-customer relationship (DoD, D-014) are addressed in the corresponding counterparty-confirmation findings (F-3, F-4). Theranos dissolved in 2018; multiple investor-litigation matters resolved through bankruptcy proceedings and counterparty settlements.

Public-Record Sources

Citations to the publicly-documented matters underpinning this analysis. All sources are independently retrievable from the issuing authority.

[1] Court filing
SEC v. Theranos, Inc. and Elizabeth Holmes, No. 5:18-cv-01602 (N.D. Cal., complaint filed Mar. 14, 2018; settled same day).
Civil enforcement complaint against Theranos and Holmes; consent judgment filed same day.
[2] Court filing
SEC v. Ramesh "Sunny" Balwani, No. 5:18-cv-01603 (N.D. Cal., complaint filed Mar. 14, 2018).
Civil enforcement complaint against the former Theranos COO and President.
[3] Court filing
United States v. Elizabeth Holmes and Ramesh Balwani, No. 5:18-CR-00258 (N.D. Cal., superseding indictment filed June 14, 2018).
Criminal indictment; Holmes convicted Jan. 3, 2022; Balwani convicted July 7, 2022.
[4] Regulatory order
Centers for Medicare and Medicaid Services, Form CMS-2567 Statement of Deficiencies, Theranos, Inc. (Newark, CA), CCN 05D2025714 (survey completed Nov. 20, 2015; issued Jan. 25, 2016).
Federal regulator finding of "immediate jeopardy to patient health and safety" at the Newark clinical laboratory.
[5] Regulatory order
Centers for Medicare and Medicaid Services, Sanction Notice and CLIA Certificate Revocation, Theranos, Inc. (Newark, CA) (issued July 7–8, 2016).
CLIA certificate revoked; two-year prohibition on Holmes from owning or operating a clinical laboratory.
[6] Regulatory order
In the Matter of Theranos, Inc., Elizabeth Holmes, and Ramesh Balwani, Administrative Proceeding File No. 3-18373 (SEC, settled order Mar. 14, 2018).
SEC administrative settlement order against Holmes; companion order to the civil filings.
[7] News investigation
John Carreyrou, "Hot Startup Theranos Has Struggled With Its Blood-Test Technology," The Wall Street Journal (Oct. 15, 2015).
Investigative report that surfaced the proficiency-testing and capability concerns publicly.
[8] Published report
John Carreyrou, Bad Blood: Secrets and Lies in a Silicon Valley Startup (Alfred A. Knopf, 2018).
Book-length account of the proficiency-testing, counterparty, and investor representations.
[9] Published report
Theranos, Inc., USPTO miniLab patent filings and office actions (2010–2015), USPTO Public PAIR.
Prosecution history establishes the patent-claim scope against which device-capability representations are measured.
[10] Regulatory order
United States Department of Defense, contract and correspondence records produced under interagency cooperation (Theranos, Inc., 2012–2015); independently corroborated against USAspending.gov public procurement registry.
Federal procurement record; documents the actual scope of the DoD relationship.
[11] Court filing
Trial testimony, United States v. Elizabeth Holmes, No. 5:18-CR-00258 (N.D. Cal., Sept. 8, 2021 – Jan. 3, 2022).
Trial record includes testimony from Tyler Shultz, Erika Cheung, and other former employees; documents whistleblower-retaliation conduct.
[12] Regulatory order
42 C.F.R. Part 493 (Clinical Laboratory Improvement Amendments standards).
Federal regulatory framework against which the CMS-2567 deficiency citations were grounded.

← Back to demo overview Process Documents →